

**University of the Philippines Manila**  
*The Health Sciences Center*  
**BIDS & AWARDS COMMITTEE IV (BAC IV)**

**Proj. Ref. No.** BAC4-21-033-D  
**End-User** Property and Supply Division  
**Project** **SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES**  
**(Immunologicals/Vaccines, Anaesthetic/Respiratory Inhalants,**  
**Liquid/Suspension Preparations, Otic/Ophthalmic Preparations**  
**External/Dermatological, Others) FOR CY 2022 (FRAMEWORK AGREEMENT) - Rebid**

**OPENING OF BIDS: 17 JUNE 2022**

ITEM NO.	QTY	UNIT	ITEM DESCRIPTION	ABC PER UNIT (PHP)	QUOTATIONS (all taxes included)	
					in figures	in words
			<b>IMMUNOLOGICALS/VACCINES</b>			
293	2,614	Pc.	Anti-tetanus serum (equine) 1500 IU/mL, 1mL ampule/vial (IM)	74.18		
294	22	Pc.	Antithymocyte Immunoglobulin (ATG) (rabbit) 25 mg/5 mL vial (IV)	13,108.61		
295	5	Pc.	Cobra antivenin 800 MU/4.8 mL, 1mL ampule (IV infusion)	1,500.00		
296	1,280	Pc.	Hepatitis B vaccine (recombinant DNA) 10mcg/0.5mL monodose vial (pediatric) (IM)	240.00		
297	475	Pc.	Hepatitis B vaccine (recombinant DNA) 20mcg/mL, monodose vial (adult) (IM)	187.44		
298	30	Pc.	Hepatitis B Immunoglobulin (human) 0.5 mL vial (IM)	1,994.00		
301	30	Pc.	Live Attenuated Measles, Mumps and Rubella (MMR) vaccine monodose vial + 0.5mL diluent (SC)	960.00		
			<b>ANAESTHETIC/RESPIRATORY INHALANTS</b>			
304	390	Pc.	Budesonide 80 micrograms + Formoterol (as fumarate dihydrate) 4.5 micrograms x 120 doses with appropriate accompanying dispenser MDI	799.00		
305	361	Pc.	Budesonide 320 micrograms + Formoterol (as fumarate dihydrate) 9 micrograms x 60 doses with appropriate accompanying dispenser DPI	1,577.49		
306	390	Pc.	Budesonide 80micrograms + Formoterol (as fumarate dihydrate) 4.5micrograms x 60 doses with appropriate accompanying dispenser DPI	793.74		
309	305	Pc.	Fluticasone propionate+salmeterol xinafoate MDI 50mcg/25mcg x 120 actuations with dose counter	161.05		
310	520	Pc.	Ipratropium bromide respiratory solution (for nebulization) 250 micrograms/mL, 2 mL (unit dose)	79.70		
311	500	Pc.	Ipratropium (as bromide) MDI: 20 micrograms/dose x 200 doses	107.25		
312	4,818	Pc.	Lidocaine hydrochloride spray 10%, 50mL	2,707.75		
314	50	Pc.	Tiotropium bromide Inhalation: 18 micrograms/dose with appropriate accompanying dispenser DPI	57.33		

Approved by:

**SGD.**  
**Dean VICENTE Y. BELIZARIO, JR., MD, MTM&I**  
*Chairperson*

\_\_\_\_\_  
*(Signature over Printed Name of President/Gen. Manager)*

\_\_\_\_\_  
*(Name & Address of Company)*

**University of the Philippines Manila**  
*The Health Sciences Center*  
**BIDS & AWARDS COMMITTEE IV (BAC IV)**

**Proj. Ref. No.** BAC4-21-033-D  
**End-User** Property and Supply Division  
**Project** **SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES**  
**(Immunologicals/Vaccines, Anaesthetic/Respiratory Inhalants,**  
**Liquid/Suspension Preparations, Otic/Ophthalmic Preparations**  
**External/Dermatological, Others) FOR CY 2022 (FRAMEWORK AGREEMENT) - Rebid**

**OPENING OF BIDS: 17 JUNE 2022**

ITEM NO.	QTY	UNIT	ITEM DESCRIPTION	ABC PER UNIT (PHP)	QUOTATIONS (all taxes included)	
					in figures	in words
			<b>LIQUID/SUSPENSION PREPARATION</b>			
317	121	Pc.	Amoxicillin trihydrate 100 mg/mL granules/powder for drops (suspension), 15 mL	23.00		
319	242	Pc.	Ascorbic acid (vitamin C) 100mg/mL, 15mL drops	33.70		
320	362	Pc.	Ascorbic acid (vitamin C) 100mg/5mL, 60mL syrup	39.50		
321	362	Pc.	Ascorbic acid (vitamin C) 100mg/5mL, 120mL syrup	73.35		
322	90	Pc.	Castor oil 60mL, USP grade	99.00		
323	251	Pc.	Cefalexin monohydrate 250mg/5mL granules/powder for syrup/suspension, 60mL	60.20		
324	246	Pc.	Cefuroxime 250 mg/5 mL granules for suspension, 50 mL content in 120 mL bottle	200.00		
325	180	Pc.	Cetirizine diHydrochloride 2.5 mg/mL syrup (oral drops), 10 mL	130.00		
326	191	Pc.	Cetirizine diHydrochloride 5mg/5mL syrup, 30mL	70.00		
327	121	Pc.	Clarithromycin 125mg/5mL granules/powder for suspension, 50mL	293.50		
329	120	Pc.	Clindamycin palmitate Hydrochloride 75mg/5mL granules for suspension, 60mL	490.00		
331	636	Pc.	Cotrimoxazole (sulfamethoxazole + trimethoprim) 400 mg sulfamethoxazole + 80 mg trimethoprim per 5 mL suspension, 60 mL	321.50		
332	122	Pc.	Diphenhydramine hydrochloride 12.5 mg/5 mL, 60 mL syrup	28.00		
333	120	Pc.	Domperidone 1mg/mL suspension, 60 mL	190.00		
334	121	Pc.	Folic Acid 5mg/5mL syrup, 60mL	217.25		
336	270	Pc.	Ibuprofen 100 mg/5 mL, 60 mL syrup/suspension	58.32		
337	150	Pc.	Ibuprofen 200 mg/5 mL, 60 mL suspension	87.50		
338	10	Pc.	Isoniazid 200mg/5mL syrup, 120 mL	74.00		
340	120	Pc.	Loratadine 5mg/5mL syrup, 30mL	95.00		
341	246	Pc.	Metronidazole (200mg/5ml as benzoate) 125mg/5mL suspension, 60mL bottle	69.00		

Approved by:

**SGD.**  
**Dean VICENTE Y. BELIZARIO, JR., MD, MTM&I**  
*Chairperson*

\_\_\_\_\_  
*(Signature over Printed Name of President/Gen. Manager)*

\_\_\_\_\_  
*(Name & Address of Company)*

**University of the Philippines Manila**  
*The Health Sciences Center*  
**BIDS & AWARDS COMMITTEE IV (BAC IV)**

**Proj. Ref. No.** BAC4-21-033-D  
**End-User** Property and Supply Division  
**Project** **SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES**  
**(Immunologicals/Vaccines, Anaesthetic/Respiratory Inhalants,**  
**Liquid/Suspension Preparations, Otic/Ophthalmic Preparations**  
**External/Dermatological, Others) FOR CY 2022 (FRAMEWORK AGREEMENT) - Rebid**

**OPENING OF BIDS: 17 JUNE 2022**

ITEM NO.	QTY	UNIT	ITEM DESCRIPTION	ABC PER UNIT (PHP)	QUOTATIONS (all taxes included)	
					in figures	in words
342	120	Pc.	Monobasic/Dibasic Sodium Phosphate 48 g/18 g per 100 mL solution, 45 mL bottle	226.50		
343	102	Pc.	Multivitamins, Infants (per 1 mL drops), 15 mL Drops Composition: Vitamin A 325 - 380 mcg; Vitamin B1 0.2 - 0.4 mg; Vitamin B2 0.3 - 0.4 mg; Vitamin B6 0.3 - 0.6 mg; Vitamin B12 0.3 - 0.4 mcg; Vitamin C 30 mg; Vitamin D 200 - 400 IU (5 - 10 mcg); Vitamin E 3 - 4 mg; Folic Acid 20 - 65 mcg; Niacin 1 - 5mg	58.88		
344	105	Pc.	Multivitamins, Children (per 5mL syrup), 60 mL Syrup Composition: Vitamin A 350 - 400 mcg; Vitamin B1 0.5 - 1.0 mg; Vitamin B2 0.7 - 0.9 mg; Vitamin B6 0.9 - 1.6 mg; Vitamin B12 0.9 - 3.0 mcg; Vitamin C 35 - 55 mg; Vitamin D 200 - 400 IU (5 - 10 mcg); Vitamin E 5 - 7 mg; Folic Acid 40 - 300 mcg; Niacin 5 - 18 mg	49.00		
345	123	Pc.	Multivitamins, Children (per 5mL syrup), 120 mL Syrup Composition: Vitamin A 350 - 400 mcg; Vitamin B1 0.5 - 1.0 mg; Vitamin B2 0.7 - 0.9 mg; Vitamin B6 0.9 - 1.6 mg; Vitamin B12 0.9 - 3.0 mcg; Vitamin C 35 - 55 mg; Vitamin D 200 - 400 IU (5 - 10 mcg); Vitamin E 5 - 7 mg; Folic Acid 40 - 300 mcg; Niacin 5 - 18 mg	97.00		
348	549	Pc.	Paracetamol 120 mg/5 mL (125 mg/5 mL) syrup/suspension, 120 mL (alcohol-free)	159.50		
350	61	Pc.	Prednisone 10 mg/5 mL suspension, 60 mL	140.00		
354	616	Pc.	Valproic Acid 250 mg/5 mL syrup, 120 mL	890.00		
355	1,460	Pc.	Zinc solution (equiv. to 10 mg elemental zinc/mL), Drops 15 mL (As Sulfate Monohydrate)	72.00		
			<b>OTIC/OPHTHALMIC PREPARATION</b>			
356	2,410	Pc.	Atropine (as sulfate) eye drops solution 1%, 5mL bottle	336.50		
357	310	Pc.	Carboxymethylcellulose sodium eye drops solution 0.5%, 15mL bottle	722.00		
363	120	Pc.	Pilocarpine (as hydrochloride) 2%, eye drops solution 15 mL bottle	270.18		
365	600	Pc.	Proxymetacaine (proparacaine) Hydrochloride eye drops solution, 0.5%, 15mL bottle	660.75		
373	300	Pc.	Tropicamide eye drops solution 0.5%, 5mL bottle	510.50		
375	120	Pc.	Indocyanine Green 25mg Lyophilized Powder for Injection in Vial	5,100.00		

Approved by:

**SGD.**  
**Dean VICENTE Y. BELIZARIO, JR., MD, MTM&I**  
*Chairperson*

\_\_\_\_\_  
*(Signature over Printed Name of President/Gen. Manager)*

\_\_\_\_\_  
*(Name & Address of Company)*

**University of the Philippines Manila**  
**The Health Sciences Center**  
**BIDS & AWARDS COMMITTEE IV (BAC IV)**

**Proj. Ref. No.** BAC4-21-033-D  
**End-User** Property and Supply Division  
**Project** SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES  
 (Immunologicals/Vaccines, Anaesthetic/Respiratory Inhalants,  
 Liquid/Suspension Preparations, Otic/Ophthalmic Preparations  
 External/Dermatological, Others) FOR CY 2022 (FRAMEWORK AGREEMENT) - Rebid

**OPENING OF BIDS: 17 JUNE 2022**

ITEM NO.	QTY	UNIT	ITEM DESCRIPTION	ABC PER UNIT (PHP)	QUOTATIONS (all taxes included)	
					in figures	in words
			<b>EXTERNAL/DERMATOLOGICAL</b>			
376	4	Pc.	Bacitracin + Neomycin + Polymixin B 200 units bacitracin + 3 mg neomycin (as sulfate) + 4000 units polymyxin B (as sulfate)/g, 10 g tube ointment	277.25		
379	24	Pc.	Hydrocortisone 1%, 10 g tube Cream or Ointment	110.00		
380	24	Pc.	Ketoconazole Cream: 2% (20 mg/ g), 15 g aluminum collapsible tube	115.00		
381	24	Pc.	Ketoconazole Shampoo: 2% (20 mg/ g), 6 mL foil sachet	59.75		
382	10	Pc.	Miconazole Topical Cream: 2% (20 mg/g), 5 g aluminum collapsible tube	398.75		
385	10,380	Pc.	Silver sulfadiazine cream 1%, 15g tube	64.77		
			<b>OTHERS</b>			
396	1,560	Pc.	Bisacodyl Rectal: 5 mg (children) suppository	32.60		
398	3,700	Pc.	Chlorhexidine solution 4%, 500mL (as gluconate) bottle	137.98		
399	5,240	Pc.	Chlorhexidine solution 0.12%, 380mL (as gluconate) bottle	292.00		
400	300	Pc.	Hydrogen Peroxide Solution: 3%, 120 mL bottle	65.00		
402	241	Pc.	Monobasic/Dibasic Sodium Phosphate Rectal: 19 g/7 g solution per 66 mL bottle (enema)	280.80		
403	660	Pc.	Monobasic/Dibasic Sodium Phosphate Rectal: 19 g/7 g solution per 133 mL bottle (enema)	213.00		
404	300	Pc.	Oxymetazoline (as hydrochloride) Nasal Drops Solution: 0.025%, 10 mL bottle Nasal Spray	297.00		
407	1,680	Pc.	Povidone iodine 1% oral antiseptic, 120ml	134.36		
408	1,704	Pc.	Povidone iodine 1% oral antiseptic, 60ml	89.00		
<b>TOTAL APPROVED BUDGET FOR THE CONTRACT: PhP22,427,816.69</b>						

Approved by:

**SGD.**  
**Dean VICENTE Y. BELIZARIO, JR., MD, MTM&I**  
*Chairperson*

\_\_\_\_\_  
*(Signature over Printed Name of President/Gen. Manager)*

\_\_\_\_\_  
*(Name & Address of Company)*

Proj. Ref. No. BAC4-21-033-D  
End-User Property and Supply Division  
Project **SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES**  
(Immunologicals/Vaccines, Anaesthetic/Respiratory Inhalants,  
Liquid/Suspension Preparations, Otic/Ophthalmic Preparations  
External/Dermatological, Others) FOR CY 2022 (FRAMEWORK AGREEMENT) - Rebid

**OPENING OF BIDS: 17 JUNE 2022**

ITEM NO.	QTY	UNIT	ITEM DESCRIPTION	ABC PER UNIT (PHP)	QUOTATIONS (all taxes included)	
					in figures	in words

**TERMS & CONDITIONS FOR THE SUPPLY AND DELIVERY OF VARIOUS DRUGS AND MEDICINES (TABLETS/ORAL SOLID) FOR CY 2022 (FRAMEWORK AGREEMENT) - REBID**

- 1 Indicate the **brand and packing of the item/s** offered.
- 2 The brand offered must be **at least five (5) years commercially available in the market from date of opening of bids**. Proof of this shall be the initial Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).
- 3 **Submit the following documents, submission should be per product, with tab and per item number. Two (2) copies for the Valid Certificate of Product Registration and Certificate of Analysis (COA).**
  - a. **Memorandum of Agreement (MOA) and Certificate of exclusive/authorized distributorship between the manufacturer and distributor.** Distributors/suppliers must have certification from their principals that they are the exclusive distributor of the drug products authorized to submit tender for the product on behalf of the principal and that all commitments made by them shall be honored by the principal in case of termination of distributorship agreement.
  - b. **Valid Certificate of Product Registration (CPR)** issued by the Food and Drug Administration (FDA).  
- **The name of the respective distributor should appear on the submitted CPR of the drug.**  
*Note: CPRs that will expire within three (3) months from the date of opening of bids should present the Official Receipt of renewal of application with the Document Tracking log for the CPR from the FDA.*
  - c. **Certificate of Analysis (COA)** for the products offered (batch to be delivered if awarded) duly issued by an FDA accredited laboratory (local) and should contain information indicated in monograph of the drug. Sample analyzed must not be expired during the time of bidding. The result of assay submitted must be in the specific brand and should be in the exact dosage formulation of the drug being bid. In cases where local laboratories are unavailable to perform drug assays, assays done abroad is accepted. The local COA is preferred and given more weight in the evaluation and awarding process.
  - d. **A notarized certificate** that it is the innovator drug (if applicable).
  - e. **Certificate of Good Manufacturing Process (CGMP).**
  - f. **Valid License to Operate (LTO).**
  - g. **A notarized certificate that the offered brand has not been subject to product complaint/product recall** for the past three (3) years.
  - h. **Certificate of Acceptance** from at least three (3) major hospitals issued within the year and should be supported with Sales Invoice (*for new item/brand offered only*).
  - i. **A notarized certificate** that there are sufficient stocks for the offered item/s for one (1) year.
- 4 The offered drug must conform to the latest Philippine Food and Drug Administration (FDA) Administrative Order governing the generic labeling and packaging requirements.
  - 4.1 **For all tablets and capsules**
    - 4.1.1 **All tablets/capsules should be in foil or blister pack. A picture of the blister pack (front and back) should be submitted.**
    - 4.1.2 Each individual flap in the tablet or capsule blister pack should be labeled with the generic name and brand.
    - 4.1.3 Dosage form and strength of the Active Pharmaceutical Ingredients (API) should appear on each unit or every 2 units for products with multiple APIs.
    - 4.1.4 Name of drug, lot or batch number and expiry date must appear on every standard blister pack/foil strip and on the container or inner packing. However, if the product is not restricted for dispensing in quantities less than the standard blister pack or foil strip, the batch or lot number and expiry date should appear on each unit.
    - 4.1.5 Inner label must be the same as the outer label.
    - 4.1.6 A complete drug literature/product insert must accompany the product.

Approved by:

**SGD.**  
**Dean VICENTE Y. BELIZARIO, JR., MD, MTM&I**  
*Chairperson*

(Signature over Printed Name of President/Gen. Manager)

(Name & Address of Company)

Proj. Ref. No. BAC4-21-033-D  
End-User Property and Supply Division  
Project SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES  
(Immunologicals/Vaccines, Anaesthetic/Respiratory Inhalants,  
Liquid/Suspension Preparations, Otic/Ophthalmic Preparations  
External/Dermatological, Others) FOR CY 2022 (FRAMEWORK AGREEMENT) - Rebid

**OPENING OF BIDS: 17 JUNE 2022**

ITEM NO.	QTY	UNIT	ITEM DESCRIPTION	ABC PER UNIT (PHP)	QUOTATIONS (all taxes included)			
					in figures	in words		
5	The following must be complied with specific for <b>inhalation anesthetics and cytotoxic injectable drugs.</b>							
	5.1	<b>For inhalation anesthetics</b>						
	5.1.1	Submit <b>certification from the bidder that inhalation bottle must be with safety sealed cap</b> , airtight and capable to dispense directly from bottle the possibility of ambient air coming into contact with agent to prevent contamination and spillage.						
	5.1.2	Submit <b>certification from the bidder that product container or anesthetic agent is shatterproof and transparent for visual check of content.</b> Container material must ensure stability of the agent to prevent degradation, must not be easy to break.						
	5.1.3	Winning bidder for Sevoflurane shall <i>provide at least thirty-five (35) vaporizers</i> on loan and in good working conditions until the validity of the contract.						
	5.2	<b>For Cytotoxic Injectable Drugs</b>						
	5.2.1	For cytotoxic injectable drugs, winning bidders are required to <i>provide Material Safety Data Sheet (MSDS) and to submit Drug Profile</i> to the Pharmacy Department per company under the first Purchase Order.						
	5.2.2	Winning bidders for cytotoxic injectable drugs are required to <b>provide at least three (3) spill kits</b> per company under the first Purchase Order.						
	5.2.3	For Paclitaxel, a special IV set must be provided per unit of the drug.						
6	<b>New brands offered</b> shall be subject to further evaluation and shall require <b>the following:</b>							
	a.	Validation of the submitted Certificate of Acceptance from at least three (3) major hospitals;						
	b.	Justification from end-user/s to validate the acceptance of the good/s offered (to be facilitated by PGH-PSD).						
7	<b>For the supply and delivery of awarded drugs and medicines.</b>							
	7.1	Delivery of the goods is required as stated in the request of the end-user, commencing on the 3rd working day of notification through confirmed fax/email that the approved Call-off/ Notice to Supplier (NTS) is already available for pick up.						
	7.2	Delivery schedule (whichever is applicable):						
		a) within seven (7) calendar days						
		b) as may be called for;						
		c) staggered delivery within three (3) months						
		* 50% of the total quantity within seven (7) calendar days and 25% each for the succeeding months						
		<i>Note: The end-user has the right to adjust the quantity to be delivered depending on the actual need of the hospital</i>						
	7.3	Deliveries shall have <b>at least two (2) years expiration date.</b>						
	7.4	Delivery of goods <b>with product complaint shall be put on hold</b> until receipt of the final decision of the PGH management whether to proceed with the acceptance or to cancel/return the items.						
	7.5	Delivered <b>items found to be non-formulary at any given time shall be returned</b> to the company and a credit memo shall be issued.						
	7.6	Stocks delivered <b>are subject to random sampling for testing</b> as to quality and conformity to label. <u>Testing fee at supplier's expense.</u>						
	7.7	Stocks with lot #/batch different from the submitted Certificate of Analysis (COA) will be subjected to testing as to quality and conformity to label. <u>Testing fee at supplier's expense.</u>						
	7.8	All items that had been pulled out for various reasons, a credit memo shall be issued by the Contractor within one (1) month, otherwise, a debit memo shall be processed by UP Manila - PGH and the amount will be deducted from any amount due to Supplier.						
	7.9	It is understood that the Supplier is legally responsible to deliver all issued <b>CALL-OFF/s (Purchase Order) and failure to deliver the first Call-Off as scheduled shall mean automatic cancellation of the Call-Off and Notice to Execute Framework Agreement (NEFA).</b> Purchase from other source for whatever means shall be effected immediately to provide the requirements of the hospital. Penalty to the defaulting contractor shall be charged accordingly.						
8	<b>Failure to comply with the submission of the required documents shall be ground for post-disqualification in accordance with RA 9184.</b>							
9	Compliance with RA 9184 and other applicable laws.							

Approved by:

SGD.  
Dean VICENTE Y. BELIZARIO, JR., MD, MTM&I  
Chairperson

(Signature over Printed Name of President/Gen. Manager)

(Name & Address of Company)